Shaping the Biotech Industry In uential
PG-26
How Digital Twins Are Quietly Rewriting the Healthcare Playbook
PG-36
The Telehealth Gold Rush Is Over. Here’s How the Smart Money Wins Now.
PG-44
Why Smart Leaders Don’t Build Their Own IDP (And What They Do Instead) CEO AlliantLabConsulting
Inaworldincreasinglydefinedbydata,discovery,anddisruption,biotechnologystandsat theveryheartofthe21st-centuryhealthcarerevolution.Fromdecodingthehumangenometo developingnext-generationtherapiesthatcanoutsmartcancer,autoimmunedisorders,and neurodegenerativediseases,biotechisnolongeranauxiliaryfield—itisthelifebloodof modernmedicine.Theyear2025hasproventobeadefiningmoment,asglobalbiotech investmentssoarpastthe$1trillionmark,drivenbybreakthroughsinAI-drivendrug discovery,syntheticbiology,andregenerativemedicine.
Yet,behindeverygroundbreakinginnovationliesavisionaryleaderwhodarestoseebeyond themicroscope—leaderswhochallengethelimitsoftraditionalhealthcareandpioneerthe futureofprecisionmedicine.Theseindividualsarenotmerelyshapinganindustry;theyare redefininghumanity’srelationshipwithbiologyitself.
ThisspecialeditionofGlobalHealthcareMagazineproudlypresents“TheMostInfluential LeadersShapingtheBiotechIndustryin2025,”featuringexceptionalpioneerswhosework bridgesscience,technology,andpurpose.
OurcoverstoryspotlightsDr.WilliamT.Budd,CEOofAlliantLabConsulting,whose journeyfromthefrontlinesofhumantraumatothefrontiersofmolecularbiology exemplifiesleadershipwithdepthanddirection.Hisstoryisoneoftransformation—oftaking lessonslearnedfromresearchandapplyingthemtothebroaderecosystemofclinical laboratories.Recognizinginefficienciesandregulatoryhurdlesthatslowinnovation,Dr Buddsteppedforwardtobuildsolutionsthatstreamlineoperationsandacceleratebiotech commercialization.Hisleadershipunderscoresacriticaltruth:thefutureofbiotechnology dependsnotjustondiscovery,butondesigningsystemsthatempowerthosediscoveriesto reachtheworld.
Thiseditionalsofeaturesotherluminariesreshapingthelandscape—Dr.StanleyT.Crooke, Dr AlbertChin,Dr.KavithaDas,andDr.LeenKawas—eachcontributingtheirunique geniustothenexteraofhumanhealthandlongevity
HappyReading!
Parag Ahire PROJECT EDITOR
PUBLISHER
ARCHANA
EDITOR-IN-CHIEF
VIKRAM
MANAGING
VISUALIZER
Tough times call for great leaders.
BeforeWilliamT.BuddwasaCEO,before
heheldaPhDinIntegrativeLife Sciences,andlongbeforehewasan expertintheintricatemolecularpathwaysof cancer,hewasamanwhounderstoodcrisis.He wasafirefighterandacriticalcareparamedic,a firstresponderonthefrontlinesofhumanfragility. Hisofficewasthebackofanambulance,achaotic, high-stakestheaterofhumanfragility.Heworked withthecriticallyillandthecatastrophically injured,peoplewhosebodieswereengagedina desperate,paradoxicalcivilwar
Inthosemoments,surroundedbytheblareofsirens andtheintricatemachineryoflifesupport,adeep fascinationtookroot.Williamobservedhowthe humanbody’sowncompensatorymechanisms,its elegantsystemsdesignedtosaveitself,could, duringperiodsofextremeillness,begintocause moredamagethantheinitialinjury.Itwasa profound,firsthandlessoninthestunning complexityandsometimestragicfallibilityof biologicalsystems.Thisexperience,witnessingthe body’sintricatesystemsbreakdownattheirmost fundamentallevel,wouldbecomeanunlikelyyet powerfulfoundationforacareerdedicatedto rebuildingthem.
Thestoryof WilliamBuddisthestoryofaman whotraveledfromthefrontlinesofhumantrauma tothefrontiersofmolecularbiology.Itisthestory ofaleaderwhounderstandsthattosolvethemost complexdiseases,youmustfirstunderstandthe complexityofthesystemsthemselves—whether theyexistwithinasinglehumancelloracrossa nationalnetworkofclinicallaboratories.
Thequestionsthataroseinthebackofthe ambulancefollowedWilliamto Virginia Commonwealth University (VCU).Hisinterestin thebody’scomplexinteractionsledhimtopivot fromemergencycaretotheintricateworldof scientificresearch.HecompletedhisMasterof ScienceinBioinformaticsin2010,followedbya PhDinIntegrativeLifeSciencesin2012,witha concentrationinmolecularbiologyand biochemistry Themacro-levelchaosoftraumacare wasreplacedbyafascinationwiththemicro-level chaosofcancer
“While at VCU, I became interested in the processes of tumorigenesis and cancer progression,” Williamrecalls.He immersedhimselfinthestudyofprostatecancer,helpingto elucidatethecrucialrolethatmicroRNAs—tiny,non-coding molecules—playintheinitiationofatumoranditsdeadly progressionintometastasis.Hewaslearningtoseediseasenot asasingleevent,butasasystemsfailure,acascadeofbroken communicationwithinthemostcomplexnetworkofall.This systemsbiologyframework,theideathatcomplexdiseasescan onlybeunderstoodbyintegratingmultiplelevelsofdata, becamehisguidingscientificprinciple.
Afteryearsinresearch,Dr Williamsawadifferentkindof systeminneedofattention:theclinicallaboratoryecosystem itself.Hesawlabsstrugglingwithinefficientworkflows, navigatingshiftingregulatorylandscapes,andtryingto commercializebrilliantnewtechnologieswithoutaclearpath tomarket.In2022,hetookthehelmasCEOof AlliantLabConsulting,acompanydesignedtoaddressthese systemicproblemshead-on.
AsCEOoftheSouthaven,MS-basedcompany,hiskey responsibilitiesarethedevelopmentandmaintenanceof strategicpartnerships.AlliantLabConsultingactsasacrucial bridgebetweenworlds.Theyworkwithclinicallaboratories, deviceandassaymanufacturers,andphysiciangroups, offeringasuiteofservicesdesignedtooptimizetheentire laboratorylifecycle.Theircoreofferingsareadirectreflection ofthepainpointsDr Williamhasobservedintheindustry:
● Validationoflaboratory-developedtests
● Installationoflaboratoryequipment
● Optimizationofworkflow
● Installationoflaboratoryinformationmanagementsystems
● Healthcarecompliance
● Revenuecyclemanagement
● Developmentofcustomassaysandgoto marketassessments
“As a clinical life science leader, I need to ensure that I remain cognizant of the quickly shifting reimbursement landscape and help our clients stay ahead of the changes,” Dr.Williamsays, highlightingoneofthemostpressingchallengeshispartners face.Anotherisstaffing.Inresponse,Alliantstarteditsown recruitingandstaffingdivision,dedicatedtocontinuously sourcingthe “best and brightest in the industry” foritsclients. Hisroleistoensurehisscientificteamshaveeveryresource theyneed,clearingthepathsotheycansolvethecomplex problemsathand.
ForDr.William,successisnotanabstractconcept;itisaset ofmeasurable,real-worldoutcomes.Whenworkingwith clinicalpartners,histeamassessessuccessthroughalensof directimpact.
● Havetheydecreasedtheturnaroundtimefortesting?
● Havetheybroughtanew,vitaltestin-housethatwas previouslyoutsourced?
● Havetheyimplementedasolutionthatallowsaclinician toinitiatedefinitivetreatmentforapatientmorequickly?
Forhisbiotechandmanufacturingpartners,thequestions arejustasdirect:
● Havesalesincreased?
● Hasthequalityoftheproductintheclinical environmentimproved?
Thisfocusontangibleresultsextendstohisowncompany’s KPIs,whichincludeincreasedtestutilizationandrevenue forclients,decreaseddenialsfrompayers,andthenumber ofprojectscompletedpermonth.Itistherigorous, data-drivenmindsetofascientistappliedtothecomplex, oftenmessy,worldofbusiness.
“Tough times call for great leaders,” Dr Williamstates. “It is easy to appear to be a good leader when things are going well. It is not clear that you’re a good leader until things are not going well.” Thisisnotatheoreticalmaximforhim;itis aphilosophyforgedinthecrucibleofprofound professionalchallenges.
Hisleadershipwasmostseverelytestedwhenhewas workingwithalargecompanythatwassuddenlyand catastrophicallyabandonedbyitsprivateequityfirm.Without warning,fundingwaspulled,andover300peoplewerelaid off.Theoperationwasinfreefall.Dr.Williamwasfacedwith themonumentaltaskofshuttingdowntheentireoperationin anorderlyfashion.Hehadtoconvinceasmall,essential contingencyofpeopletoremainbehindandhelphim,all withoutanyguaranteethattheywouldbepaidfortheirwork.
Itwasamomentthatstrippedleadershipdowntoitsmost essentialelement:trust “Thankfully, there were a number of people that respected and trusted me enough to help,” Dr.Williamrecalls.Thatagroupofpeople,inthefaceof suchuncertaintyandbetrayal,chosetostayandwork alongsidehimisperhapsthemostpowerfultestamenttohis leadershipstyle,onethatinspiresloyaltyeveninthedarkest oftimes.
Thisexperiencestandsinstarkcontrasttowhathedescribes ashishighestmoments: working with and mentoring junior scientists.Hefindsimmensejoyin “seeing the excitement they feel when they are able to make connections between didactic and experimental work.” Itistheheartofateacher,a leaderwhofindsfulfillmentinempoweringothers.
OneofDr.William’sproudestandmostimpactful accomplishmentscameattheverydawnoftheCOVID-19 pandemic.Atthetime,hewasworkingforasmallclinical toxicologylaboratoryandhadbeenhiredtostartamolecular diagnosticsprogram.InlateDecember2019,withthefirst whispersofanovelcoronavirusemergingfromChina,hehad theforesighttoreachouttoacorporatecontactintheUK. Together,theybegantocollaborateondevelopingaPCR assayforSARS-CoV-2.
ByFebruary2020,beforethevirushadfullygrippedthe world,theyhadsuccessfullydevelopedandvalidateda clinicalassay.ByearlyMarch,whentheneedbecame critical,theywereready
“
It is easy to appear to be a good leader when things are going well. It is not clear that you re a good leader until things are not going well.
CoverStory
“We scaled quickly to provide results on the same day of receipt for over 3000 samples at a time other national labs were taking up to 7 days to report results,” Dr.Williamsays.Theyworkedcloselywith publichealthpartners,implementingdrive-through testingsitesinmultipleareasattheheightof thepandemic.
Buttheinnovationdidn’tstopthere.In2021,as multiplevariantsbegantocirculate—variantsfor whichtreatmentoroutcomesmightdiffer—histeam developedaclinicalassaythatcoulddeterminethe specificvariantinrealtime.Itwasaremarkablefeat ofspeed,foresight,andscientificrigorthat undoubtedlysavedlivesandprovidedcriticaldata whentheworldneededitmost.
Lookingahead,Dr.Williamismostexcitedbythe potentialofartificialintelligence,particularlylarge languagemodels(LLMs),totransformtheclinicallab industry.HeseesafuturewhereAIcanhelpidentify gapsincareandrecommendpotentialsolutions directlytoclinicians,creatingamoreintelligentand responsivehealthcareecosystem.
ForAlliantLabConsulting,thenextyearwillbe focusedoncontinuingtodevelopstrategic partnershipswithvendorsanddevicemanufacturers. Heisalsokeenlyinterestedintheburgeoningfieldof direct-to-consumer(DTC)testing,seeingthe continuedshiftoftestingfromthedoctor’sofficeto thehome.
Throughitall,Dr.Williammaintainshisbalanceby ensuringhetakestimeoffeveryfewmonthstoget away,reset,andrefresh.Itisanecessarypracticefora leaderwhohasspenthiscareerrunningtoward,not awayfrom,themostcomplexchallenges.Fromthe backofanambulancetothefrontiersofAI,William Buddhasneverlostthecoreinsightthatinspiredhim fromthebeginning:thatthebestwaytohealistofirst understandthesystem,andthenhavethecourage,the vision,andtheleadershiptobuildabetterone.
www.alliantlabconsulting.com
www.purposemedsolutions.org
Theultimategoalinvolvesplacingthedevice non-surgicallyinacatheterizationlab.Dr.Chin andhisteampresentedthebiomechanical principlesbehindthedevice,asummaryofthe preclinicaltestsconducted,andinitialdatafrom humanuseatakeymedicalconference.They sharedthisinformationatthe70thannual meetingoftheAmericanSocietyofArtificial InternalOrgans(ASAIO)inApril2024in Baltimore.Thispresentationmarkeda significantstepinbringingthispotentiallylifesavingtechnologyclosertowiderpatientaccess.
Dr.AlbertChin’sstartupcompaniesaimto simplifythedesignoftheirinnovativemedical deviceswhileensuringtheyremainfunctional andeffective.Achievingthisbalanceoften requiresadvancedtechnology Thisincludes improvementsinmaterials,manufacturing techniques,sensors,electroniccontrols,and softwaredevelopment.
ThePercAssistcardiacassistballoonprovidesa primeexample.Hedesigneditforpatientswith heartfailure.Thisdeviceinflateswitheach heartbeat,triggeredbythepatient’sECGsignal. Itaimstoserveasalong-termimplantable solutionforend-stageheartfailurepatientswho arenotsuitablecandidatesforheart transplantation.Thedesigndemandsextreme reliability.Theballoonmustendureover40 millioncyclesofinflationanddeflationwithina yearbeforereplacement.Initially,Dr.Chinused aninelasticpolyethyleneterephthalate(PET) balloon.Testsfounditinadequateduetoearly ruptures.Afterfurthertesting,histeamidentified apartiallyelasticpolyurethanematerial.This materialachieved60millioncyclesduring manufacturingtests,meetingthestringent durabilityrequirements.
Additionally,thesoftwarecontrolsforthe cardiacassistballoonensureproperfunction. Theballooninflatesduringtheheart's contractionphase(systole)basedontheECG signal.Analgorithmminimizesanydelay betweenthesignalandballooninflation.This allowsthedevicetoaccommodateheartratesof upto130beatsperminute
Dr AlbertChin’sdesignphilosophyemphasizessimplicity This approachmakeshisnoveldevicessuitableforrobotic-assisted techniquesinthefuture.Integratingadvancedtechnologies allowshisdevicestobenefitfromtheanalysisandmodulationof largedatasetsofphysiologicalparametersthroughartificial intelligence.
Asnewdevicesandtherapiesareintroduced,theyundergorapid improvements.Thisprocessreliesoninitialclinicaluseand feedbackfromphysicians.Thisallowsforthecontinuous evolutionofthedevices.Itincorporatesadvancedtechnologies intotheoriginaldesigns,ensuringtheybecomemoreeffective andeasiertouseovertime.
Dr AlbertChin’sstartupmedicaldevicecompaniesactivelyseek strategicpartnershipswithestablisheddevicecompanies.They currentlyengageincommunicationduringthedevelopmentand clinicaltrialphases.PercAssist,Inc.,withitsuniqueplatform approach,demonstratesparticularopennesstocollaboratingwith largercompanies.Thisdeviceiscrucialforsustaininglife.Itwill requirealarge-scalepivotalclinicaltrialforregulatoryapproval. Typically,majormedicaldevicecompaniesprefertoconduct thesepivotaltrialsundertheirdirectoversight.
Meanwhile,Dr.Chin’sotherstartupcompaniesworkonproducts thatwillrequire510(k)clearancefromregulatorybodies.These productswillfocusoncommercializationandmarket development.Theywillthenbecomecandidatesforacquisition byestablishedentities.
Thehealthcareindustrychangesquickly.Dr AlbertChin identifiesimportanttrendsthatwilllikelydefineitsfuture. Traditionally,medicaldeviceshaveprovidedtreatmentafteran illnesshasoccurred,representingareactiveapproach.However, thefuturemayfocusmoreonproactivecare.Itwillaimto preventillnessesbeforetheyhappen.
Bothcardiovasculardiseaseandcancerhavegeneticcomponents. Thisopensthedoorforinnovativesolutionsrootedingenetic understanding.Advancesinbiologicalengineering,particularly throughgeneediting,couldallowforearlyintervention.This couldaddressdiseaseslinkedtogeneticmutationsorcongenital conditions.Thisshifttowardspreventioncouldsignificantly improvepatientoutcomes.Itpossessesthepowertoreshapehow healthcareisdeliveredglobally
You’renottheonlyversionofyourselfanymore.
Somewhere—inaserverfarmyou’llnevervisit,running codeyou’llneversee—yourdigitaldoublequietly watchesyou.Itlearnsfromyourbloodwork,your medicalhistory,yourheartbeat.Itdoesn’tsleep.It doesn’tforget.Andit’snotjustrecording.It’sprojecting.
Thisistheworldofmedicaldigitaltwins.Andifyou’re stilltreatingthemlikefuturisticnovelties,you’relate. Thisisn’taboutgadgets.Thisisaboutleverage.Thekind ofleveragethatCEOsuseintheboardroomto outmaneuvertheircompetitors.Thekindofleverage hospitalswillneedtosurviveaworldwherepatients behavelikeconsumersanddatadriveseveryclinical decision.
Let’sbeclear:digitaltwinswon’tjustenhance healthcare.Theywillreplacetheguesswork.
Stripawaythetechlingo.Here’sthetruth.
Amedicaldigitaltwinisyourbiologicalreflectionincode.It’s avirtualversionofyou—fedbyyourgeneticprofile, wearables,bloodtests,imagingscans,andmore.Itruns simulations.Itwatchesfordeviations.Itruns“what-if” scenarioslongbeforeyourbodybreaksdown.
It’snothypothetical.It’smathematical.
Builtwithmachinelearningmodelsandreal-timephysiological data,thetwincansimulatehowyourbodymightrespondto differenttreatments,diets,drugs—evenfuturediseases.
Thisisnolongeralabprototype.It’sbeingdeployedrightnow inpilotprogramsfromBostontoBarcelona.Andtheearly signals?They’renotjustpromising—they’redecisive.
WhatYou’reMissingIfYou’reNot PayingAttention
Mosthealthcaresystemsstilltreatpeoplelike theyliveinsidespreadsheets.Age,weight, BMI.Baselines.Averages.Thesearen’t insights—they’reshortcuts.
Adigitaltwindoesn’tcareaboutaverages.It models you—downtothecellularlevelif needed.
Andhere’sthestrategicshift:
Withatwin,doctorsstopreacting.Theystart anticipating.
CaseinPoint:TheHeartThatWarnsYou BeforeItFails
AttheBarcelonaSupercomputingCenter, researchersdidn’tbuildatool.Theybuilta revolution:adigitaltwinofthehumanheart calledAlyaRed.
100millionvirtualheartcells.50equations percell.Ittakes10hourstosimulate10 heartbeats.Whydoesthatmatter?
Becausethisheartcanspotfailuresbefore symptomsshowup.Itseeswhatmedication willfixyou before youneedthemedication. That’snottheory.That’strajectory.
Imagineyou’reacardiacpatient.Wouldyou ratherwaitforchestpain—orseeasimulation flagdeterioratingbloodflowinreal-time?
ThisiswhatAlyaReddelivers.Strongflows appearasredandorange.Sickzonesglow blueandgreen.Thecolortellsthestory. Doctorsdon’tguess.Theyact.
Let’sTalkStrategy:WhatDigitalTwins ActuallyChange
1.TheyKilltheStandardProtocol
Yourtreatmentisn’tbasedonpopulationleveltrialsanymore.It’sbasedonyourown future.
CEOstalkabout“precisionstrategy.”Thisis “precisioncare.”It’sthesameprinciple. Understandthelandscape,simulateoutcomes, executetheoptimalplay
2.TheyFliptheHealthSystemIncentives
Today,providersprofitwhenpeoplestaysick longer.Buttwinsenableearlyintervention.That onlyworksinavalue-basedcaremodel.Soif you’renotshiftingyoursystemnow,you’re bettingagainstthetrend.
3.TheyEmpowerthePatient—andForce Transparency
Patientswhoseetheirdigitaltwindon’tstay passive.Theyaskquestions.Theywantreal answers.Andtheycanseewhensomething doesn’taddup.Ifyou’reaprovider,thismeansno morevagueadvice.Yourdatawillbematched againsttheirs.
WhattheSmartSystemsAreDoingRightNow
Let’smakeitreal.
Here’swhatthetop-tierhealthsystemsand tech-forwardclinicsaredoingtodaywithdigital twins:
· RiskMapping:Usingpersonaltwinsto simulatehowlikelyapatientistodevelop diabetes,cancer,orstroke—before any symptomsarise.
· TreatmentSimulation:Tryingoutfive differentchemoregimensonthedigital versionofacancerpatienttoidentifythebest option—before startingasingledose.
· SurgicalPrecision:Pre-testingsurgical proceduresinthevirtualbodytoreducepostopcomplicationsandlowermalpracticerisk.
Thisisstrategydisguisedascare.Anditworks.
ButThere’saCatchNoOneTalksAbout
Digitaltwinsdon’tworkinisolation.Theyneed infrastructure.Cleandata.Securesystems.A clinicalteamthatknowshowtouseinsights—not justcollectthem.
Mostprovidersaren’tready.Andtheoneswhoare? They’renottalking.Becausewhenyougetthisedge, youdon’tbroadcastit.Youscaleit.
Andthatbringsustotheuncomfortabletruth:
Digitaltwinswon’tdemocratizehealthcare.They’ll weaponizeit—forthosewhoprepare.
Ifyou’readecision-makerinhealthcare—clinical, operational,orstrategic—askyourself:
· Isoursystemstructuredtotreatpatternsorpeople?
· Doourcliniciansknowhowtointerpretsimulation data?
· HaveweinvestedintheITbackbonethatsupports twin-basedcare?
· Arewestillreactingtodisease…oranticipating it?
Thewinnersinthenextphaseofhealthcarewon’tbetheones withthebestslogans.They’llbetheoneswhoknowwhat’s coming—becausethey’vealreadyseenit.
FinalWord:ThisIsn’ttheFuture.It’sAlreadyHere.
Thephrase“personalizedmedicine”hasbeenaroundfortwo decades.Butnow,itmeanssomethingveryreal.Itmeansyour body,renderedindata.Simulated.Projected.Protected.
InthewordsofoneCTOataleadingbiotechfirm:
“Westoppeddesigningtreatments.Westarteddesigningfutures.”
That’sthedifferencedigitaltwinsmake.
Andifyou’restillthinkingofthisasatechnologystory,you’re missingthebiggerplay.
Thisisastrategystory.Acontrolstory.Asystems dominancestory
Effectiveleadershipandimpactful
researchintoday’scomplex healthcarelandscapeoften involvesaddressingtheintersectionsof clinicalcare,evidence-basedresearch,access tocareprinciples,andeffectivemanagement. Dr.KavithaDasoperatespreciselyatthis convergence.Sheleveragesherdiverse backgroundindentistry, medical-dental integration,publichealth,andresearch experiencetodevelopandimplement initiativesaimedatimprovinghealth outcomesandaccesstocare.Herwork focusesparticularlyonaddressingsystemic fragmentationinhealthcareandpromoting preventiveandearlydetectionstrategies.
Dr.Das’scommitmenttohealthpromotion anddiseasepreventionbeganearlyinher careerasanewlygraduateddentistin Bangalore,India.Whileworkingalongside anoralandmaxillofacialsurgeon,she witnessedthedevastatingeffectsofdelayed healthcare.“Wesawnumerouspatients presentingwithearly-stageoralcancers,” sherecalls.Thetroublingrealitywasthat manydidnotreturnforfollow-upcare Whentheyreturnedmonthslater,their cancershadsignificantlyprogressed,often requiringextensivesurgeryand chemotherapy.
“This experience deeply impacted me,” Dr Dasreflects.“Ithighlightedthecritical roleofhealtheducation,publicawareness, androutinewellnessscreeningsin improvingpatientoutcomes.”Thedesire “tomakeabroaderimpact”setheronanew trajectory.
ThisrealizationmotivatedDr.Dastopursue aMasterofPublicHealth(MPH)inSocial andBehavioralSciencesandInternational HealthfromBostonUniversity.This programprovidedherwithaframeworkfor understandinghealthchallengesata populationlevel.
Afterward,shereturnedforintensive clinicaltraining,completingasecond residencyandearningaMaster’sdegree inProsthodonticsfromColumbia UniversityCollegeofDentalMedicine. Asshemasteredcomplexdental rehabilitation,sheencountereda recurringtheme:thecriticalimportance ofpatientunderstanding.
“Irealizedonceagainhowessential patienteducationisforensuringthe long-termsuccessandmaintenance ofimplant-supportedtreatments.” Sheclearlyrecognizedthesignificant savingsinbothcostandsufferingthat couldbeachievedthroughearlier intervention.
“Since completing my MPH, my work has consistently taken an interdisciplinary approach,” Dr.Das notes.Herpathincluded:
● Programmanagementandresearch inHIV/AIDSatYaleUniversity SchoolofPublicHealth
● Theresearchfocusedonolderadult healthatColumbiaUniversity.
● Aneight-yeartenureasaSenior ScientistinCardiologyatthe IcahnSchoolofMedicineat MountSinai,whereshe investigatedthecruciallinks betweencardiovasculardisease, diabetes,andoral-systemichealth.
Duringtheseyears,akeyobservation emerged.Dr.Dasnoted,“Iobserved thatdentalandmedicalprofessionals oftenworkinsilos,resultingin fragmentedcarewherethepatient ultimatelysuffers.”Itwasacallto action. “This realization led me to shift my focus toward translating research into practical, community-based solutions that improve care access to care across all populations.”
Dr.Dasnowchannelsherexpertiseintokey leadershiprolesinresearchandtranslational science.Shefocusesonenhancingeldercare throughherrolesasaDirectorforResearch andManagementinmultiplesettingslike adultdaycarecentersandnon-profitsectors byintegratingvarioushealthservices, implementingandevaluatingresearch findings,andtailoringprogramstoimprove thequalityoflifeforseniors.
Dr.KavithaDashasalsobeenleadinghealth policyandadvocacyeffortsforover10 years.ShewastheCo-ChairforHealth PolicyandAdvocacyforthePublicHealth AssociationofNYC,andnowservesasthe
ChairforthePolicyandAdvocacy CommitteeforNYCattheNewYork StatePublicHealthAssociation.Inthis role,sheworkswithhealthcareand publichealthprofessionalstoeducate thepublicandlegislatorsonhealth issuesthatareharmfultothepopulation.
Dr.Dastakesonahands-onrole, describingherselfasa“jackofall trades”involvedingrantwriting, research,proactivepopulationoutreach, andfosteringcollaborationsacross healthcare,industry,andtechnology sectors.Sheaimstoalleviatetheburden ofdiseasethroughinnovation, prevention,earlydetection,precision medicineandhealtheducation.
Acrosshervariousroles,Dr.Dasemploysaconsistentset ofcorestrategiesgroundedinherdiversebackground:
● InterdisciplinaryCollaboration:Dr.Das emphasizes, “Collaboration is key,” highlightingthe importanceofengagingwithawiderangeof stakeholders,includingindustryleaders,faith-based leaders,healthcareprofessionals,academics, communityleaders,legislatorsandbiotechinnovators. Herabilitytonavigatethesediverseinteractionsis partlyattributedtoherexperiencelivingin multiculturalenvironmentssuchasBangaloreand NewYorkCity.Herapproachfocusesonfostering trustandrapport,maintaininganopen-doorpolicyfor stakeholders,andbuildingcomplementaryteamsand alliances.
● FocusonPrevention&EarlyDetection:Drawing directlyfromherearlyclinicalexperiences,Dr.Das activelypartnerswithorganizationsprioritizing preventionandearlyinterventionfornoncommunicablediseaseslikediabetesandheartdisease. Shechampionstheuseofdigitalhealthtoolsthatserve dualroles:educatingindividualsandempowering them “to take responsibility for their own health without judgment.”
Anotableexampleofherproactiveapproachwas pioneeringtheuseofhighaccuracypoint-of-care (POC)testinginNewYorkCityschoolsduringthe COVID-19pandemictominimizevirusspreadand facilitateareturntoin-personlearning.Shecontinues toexplorepartnershipsinvolvingnewPOCtesting devicesandmobileapplicationsforearlydetectionof conditionslikecervicalcancer,metabolicdiseases, irondeficiencyanemia,andbeta-cellthalassemia.
● TechnologyIntegration:Centraltoheruseofdigital healthtoolsandPOCtestingisastrategyofleveraging technologytoenhanceaccessandimprovehealth outcomes.Dr.Dasactivelyseekspartnershipswith healthtechinnovatorstoincorporatenovelapproaches intocommunity-basedandcorporatehealthprograms.
● PolicyandAdvocacy:Knowledgeispowereducatingpeopleacrossdiversegroupsisvitaltothe uptakeanduseofevidence-basedhealthresearch outcomesanduseofnewhealthtechnologytoolsto minimizethelongtermimpactofchronicdiseases.
Leadingchangealwayscomeswithchallenges.Dr.Das highlightsthedifficultiesinchangingestablished mindsetswithinthehealthcaresystem,whichshenotes isprimarilyfocusedonpatientcare.Sheexplainsthat persuadingstakeholderstoadoptamorecomprehensive approach—onethatincludespreventionandearly detection—isoftencomplicatedbytheiremphasison short-termgoals.
Theseimmediateneedsfrequentlyoverlookthelongtermbenefitsofprevention,whichhasbeenshownto savemoneyandreducesuffering.Asaresult,Dr.Das feelstheneedtobecreativeinherstrategies,workingto bridgethegapbetweenstakeholders’immediate requirementsandtheirlong-termobjectives.
Dr.Dasmaintainsenergyforherdemandingroles throughactivitiesoutsideherdirectprofessional commitments.SheispartofagroupinNYCwhoare knowninNewYorkCityfororganizing “entertaining events in the fundraising space,” citingexampleslike salsadancingnights,chocolatetastings,fashionshows, and5krunsaspersonalstressrelievers.
Moreover,shevaluestimespentunwindingwithfriends andfamily,acknowledgingtheircrucialsupport.Her coreleadershipphilosophyappearsstraightforwardyet powerful:“Lovewhatyoudo,anddoitwell-people aredrawntogenuinepassionandpurpose.”This principleseemstofuelherdedicationacrossherdiverse responsibilities.
Lookingforward,Dr.Dasremainsfocusedoncreating scalableandimpactfulsolutions.Ifgrantedunlimited resources,herfocusturnstofundamentaldeterminants. “Poverty is directly linked to poor health,” sheasserts. Herprioritywouldbe“povertyeradication,while simultaneouslyfocusingonskillbuildingand nutritioneducationusingeasilyaccessibledigital toolsandculturallytailoredmessages,sothatthe individualenjoyslearning!”
Theemphasisonengagementiscrucial:“Making learningenjoyable...aresurefirewaystoencourage themtocontinuetheirjourneytowardbetterhealth.”
2.TheyCreatedaDisconnectedExperience: Mostoftheseappsexistonanisland,completely detachedfromthecoresystemsofcare.The clinicianhastoexittheirEHR,logintoaseparate system,conductthecall,thenreturntotheEHRto documentit.Thepatienthasaseparatelogin,a separateinbox,andaseparateexperiencethatfeels divorcedfromtheiroverallcarejourney.This fragmentationcreatesmoreworkforyourstaffand adisjointed,frustratingexperienceforyour patients.Itsolvesoneproblem(thevisit)by creatingthreemore(documentation,navigation, andfollow-up).
3.TheyWereEmptyWaitingRooms:Themantra was“ifyoubuildit,theywillcome.”Itwasalie. Buildingthetechnologydidnotmagicallyrewire decadesofpatientbehaviororcomplexclinical workflows.Theseappsweresolutionsinsearchofa definedproblem.Theylackedaclearstrategyfor clinicianadoptionbeyondatop-downmandate,and theyhadnoplanforpatientengagementbeyondthe initialnovelty Theywereemptydigitalrooms waitingforpeoplewhonevershowedupin sustainablenumbers.
TheStrategicPivot:From“App”to“Platform”
Thesmartmoneyisnolongerfunding“telehealth apps.”ItisfundingthecreationoftrueVirtualCare DeliveryPlatforms.Aplatformisnotatool;itisa fundamentalre-architectureofhowyoudeliver care.Itisbuiltonthreestrategicpillarsthatcreatea defensible,high-valuesystem.
Pillar1:DeepClinicalWorkflowIntegration (TheEngine)Atrueplatformdoesnotsitontopof theworkflow;itiswovenintoitsveryfabric.Itis theengine,notasidecar.
· YourMandate:Theplatformmusthavedeep, bidirectionalintegrationwithyourEHR(Epic, Cerner,etc.).Itmustpullpatientdatatogivethe cliniciancontext before thevisitandpushvisit data,notes,andordersbackintotheEHR automatically.Itautomatesscheduling,coding, andbilling.Thegoalissimplebutpowerful:the platformmustreducetheclinician’stotal workload,notaddtoit.Thisistheonlywayto achievetrue,enthusiasticadoptionfromyour mostvaluableasset:yourproviders.
Pillar2:ContinuousPatientEngagement(TheMoat) Acommodityappistransactional.Aplatformis relational.Itsjobisnotfinishedwhenthevideocall ends.Itisdesignedtomanagethepatient’sjourney between visits.
· YourMandate:Youmustbuildamoataroundyour patientrelationship.Thismeansintegratingtoolsthat createcontinuousvalue.RemotePatientMonitoring (RPM)forchronicdiseasemanagement,wheredaily vitalsaretrackedautomatically.Secureasynchronous messagingfornon-urgentfollow-upquestions. Personalizededucationalcontentpushedtothepatient basedontheircondition.Integratedprescription managementandadherencetracking.Thisecosystem ofcontinuouscarecreatesimmense“stickiness.”It makesswitchingtoacompetitor’scommodityapp unthinkableforthepatient.
Pillar3:DataasaStrategicAsset(TheFuel)Asimple appgeneratesarecordofatransaction.Aplatform generatesalongitudinaldatastream.Thisisitsfuel.
· YourMandate:Youmusttreatthedatafromyour platformasacorestrategicasset.Byanalyzingpatient engagement,RPMdata,andclinicaloutcomesover time,youcanmovefromreactivesick-careto proactive,predictivehealth.Youcanidentifyat-risk patientsbeforetheydecompensate.Youcanprove yourplatformimprovesoutcomesandlowersthetotal costofcare.Thisdataiswhatyouwilluseto negotiatefavorabletermswithpayersandto demonstrateyourclinicalsuperiorityinthemarket.
TheExecutionMandate:ForgingYourVirtualCare Platform
Buildingatrueplatformrequiresalevelofstrategicrigor absentfromthegoldrush.
1.DefineYourBeachhead,ThenDominate:Donottry tobeeverythingtoeverypatient.Thatisarecipefor failure.Instead,identifyaspecificclinicaloroperational beachheadwhereyoucanestablishdominance.IsIt post-operativeorthopediccare,whereRPMcanreduce readmissions?Isitchronicdiabetesmanagement,where continuousengagementiskey?Isitdermatology,where asynchronouscaremodelscanbehighlyefficient?Pick oneniche.Perfectyourplatform,proveitsclinicaland financialvalue,andthenexpandfromthatpositionof strength.
2.PartnerwithanArchitect,NotaBuilder:Stoplooking fora“telemedicineappdeveloper.”Youarenotbuilding fromagenericfeaturelist.Youneedtopartnerwitha virtualcarearchitect.Thisisateamwhosefirstquestions areaboutyourclinicalworkflows,yourEHRintegration points,andyourbusinessgoals—notyourcolorpalette. Theirdeepexperiencewithhealthcareinteroperability standards(HL7,FHIR)andEHRsystemsisinfinitelymore valuablethantheirabilitytocodeaslickfront-end.Vet themontheirstrategicunderstandingofhealthcaredelivery, notjusttheirtechnicalskill.
3.TheFutureisAsynchronous:Themostsignificant, immediateopportunityforefficiencyandscaleisnotAIor blockchain.Itisasynchronouscare.
Thismeans“store-and-forward”interactionswherepatients andclinicianscommunicateontheirowntime.Apatient sendsasecuremessagewithaphotoofaskincondition. Adermatologistreviewsitbetweenscheduled appointmentsandsendsbackadiagnosisandprescription. Adiabeticpatientuploadstheirglucosereadings,anda nursereviewsthedataandadjuststheircareplanlaterthat day.
Thismodelbreaksthetyrannyoftheone-to-one,real-time appointment.Itallowsonecliniciantomanageamuch largerpanelofpatientswithincredibleefficiency
Yourplatformmustbebuiltfromthegrounduptosupport bothsynchronous(livevideo)andasynchronous workflows.Thisdualcapabilityisamassivecompetitive advantage.
TheChoice:DigitalWaitingRoomorVirtualCare System?
Thefirst,chaoticchapterofremotecareisclosed.The marketismaturing,andthestandardsforsuccessare risingdramatically.Continuingtooperateastandalone, commoditytelehealthappisnolongeraviablestrategy.It isaslow-motionsurrender
Theopportunitybeforeyounowistobuildadurable, strategicasset.Tomovebeyondthedigitalwaitingroom andconstructatruesystemofvirtualcaredelivery—one thatisdeeplyintegrated,continuouslyengaging,and fueledbydata.
Thisistheworkofseriousleaders.Itrequiresinvestment, discipline,andaclear-eyedviewofthecompetitive landscape.
So,thechoiceisyours.Willyoukeeppatchingtheroofof asimpledigitalwaitingroom?Orwillyouarchitectthe integratedvirtualcaresystemthatwilldefinethefutureof yourorganizationandbecometheengineofitsgrowth?
Dr.LeenKawasknowswhatittakestodisruptan
industryandshehasdoneitwithbiotechinwaysfew couldimagine.Frompioneeringdrugdevelopments forAlzheimer’stofoundingPropelBioPartners,alifescience investmentfirm,she’sbreakinggroundnotjustintreatments, butinhowtheentiresectorthinksaboutinvestment,growth, andinclusivity
Herstoryisnotoneofluckoreasysuccess.Everymilestoneis hard-won,groundedinrelentlessinnovationandaneyefor opportunitythatfewotherscansee.ForLeen,themissionhas alwaysbeenclear:developsolutionsthathavereal,lasting impactsonhumanhealth.Thismeansdiscoveringandinvesting intechnologiesthatothersmightoverlookbutthatsheknows canchangelives.
TheRiseofaBiotechPioneer
Leen’sjourneyinbiotechdidn’tstartwithacushyroleor generousfunding.Shebuiltherexpertiseandcareerfromthe groundup.In2014,sheco-foundedAthiraPharmaandbrought ingroundbreakingideasaroundneurologicaldiseases.In biotech,thepressuretodeliverisn’tjustonprofitsbuton producingtangible,life-savingresults.Leen’srelentlessdrive helpedherraiseover$400million,culminatinginoneofthe industry’smostnotableIPOs,andshediditwhilebreaking stereotypesleftandright.
What’sthesecret?Leenfocusesonthebigpicturewhilezeroing inoneverydetail.Shedoesn’tjustwantnewtherapiesinthe market—shewantstoreshapehowpatientsreceivethem,how researchersthinkaboutthem,andhowinvestorssupportthem. It’savisionthatgoesbeyondproducts;it’saboutshapingthe futureofhealthcare,andshe’sjustgettingstarted.
NowatPropelBioPartners,LeenleadsasManagingGeneral Partner,targetingaveryspecificchallenge:findingthebiotech firmswithpotentialfortransformationalchangeandgivingthem thesupporttheyneedtogetthere.PropelBioPartnersisnotjust anotherinvestmentfirm;it’saplatformbuiltaround collaborationandsupportforhigh-potential,early-stagelife sciencescompanies.
“We’reinvestinginpeopleandideasthathavethe potentialtofundamentallyimprovelives,”shesays. Withafocusonbothsmall-cappublicandprivate companies,PropelBioistakingaholisticapproach. ForLeen,eachinvestmentdecisiongoesbeyond finance;itinvolvesevaluatingthetechnology,the team,andtheimpacttheycouldhaveonthefuture ofhealthcare.Hereyeforfindingandnurturing potentialdoesn’tjustcomefromyearsof experiencebutfromadeep-rootedbeliefinwhat biotechcanachievewhenfueledbytherightvision andvalues.
Inasectorwhereinnovationandprogressarekey, Leenhasseenthatforwomen,thepathisoften morechallenging.She’soneofjust22female foundersandCEOstotakeacompanypublicin biotechasof2021—astaggeringstatisticthat underscorestherarityofheraccomplishment. Despitetheseodds,Leendidn’tjustnavigatethe biotechlandscape;shereshapeditforherselfand thosewhocameafterher.
Butit’snotjustaboutbreakingrecords.Leenknows thatleadingacompanyinbiotechmeans confrontingauniquesetofchallenges.Whenshe ledAthirathroughitsIPO,itmarkedthefirsttime inover20yearsthatawomanhadguidedabiotech companytopublicstatusinWashingtonState.The recognition,whilesignificant,onlymadehermore awareoftheworklefttodoforwomeninscience andleadership.
“It’sharderasawoman;there’snodoubtaboutit,” shesays.“ButIdidn’tletthatdefinemeorlimitmy goals.”ForLeen,thefocusisclear:build companiesthatcanstandthetestoftime,andcreate pathwaysforotherwomentodothesame.It’san approachthathasseenhergainnotonlyindustry accoladesbutalsothetrustandrespectofanew generationoffemalescientistsandentrepreneurs.
TounderstandLeen’sleadership,looknofurtherthanher workatAthira.Asco-founder,shedidn’tjustoversee operations;shewasdeeplyinvolvedinscientificresearch anddrugdevelopment.Athira’sleadcandidate,ATH-1017, aimedattreatingAlzheimer’s,representsoneofhermajor contributionstothefield.Bringingthistoliferequirednot onlyscientificacumenbutalsothetenacitytosecure fundingandnavigatethecomplexitiesofclinicaltrials, regulatorypathways,andpublicinterest.
Raising$400millionandsuccessfullytakingAthirapublic, Leenputherself—andthecompany—onthemap.Shesays, “Thehardworkwasn’tjustingettingtotheIPO;itwasin ensuringthatwhatwewerebuildinghadrealsubstance, realpotentialtochangelives.”Thatclarityofpurposegave hertheedgeneededtoseethecompanythroughitsmost challengingtimes,includingtheimmensepressurethat comeswithapubliclisting.
Today,atPropelBioPartners,Leenleverageseverything shelearnedfromheryearsatAthira.She’snotinterestedin beingapassiveinvestor;she'sactivelyinvolvedinguiding portfoliocompanies,offeringstrategicinputoneverything fromregulatorypathwaystoproductdevelopment.Propel Bioisn’tjustaboutinjectingmoney—it’saboutbeingpart ofthejourney,ensuringthatthecompaniestheysupport havetheresourcesandguidancetheyneedtosucceed.
PropelBioPartnersoperatesonasimplebutpowerful premise:realtransformationinhealthcaretakesmorethan justcapital;ittakesacommunityofexpertsandadvisors. Byprovidingthisnetwork,Leenandherteamare rethinkingwhatitmeanstobealifesciencesinvestor “Everycompanyweworkwithispartofalargermissionto createbetter,moreeffectivehealthcaresolutions,”shesays. ForLeen,it’snotenoughtoseeapromisingtechnology; sheneedstoknowithasthepotentialtobenefitpatientsand thatit'sbeingledbypeoplewhosharethatcommitment.
Beyondtheboardroomandlab,Leen’svoiceisoneof advocacy.Sheactivelysupportsgenderequity,butnotina performativeway.AtPropelBio,herfocusondiversityin portfoliocompanieshappenednaturally,withamajorityof herfirm’sinvestmentslandinginwomen-ledventures.
ForLeen,itwasn’taquotatobefilledbutratherareflectionof herbeliefthatgreatideascancomefromanyoneandshouldbe supportedwherevertheyarise.
“Sometimes,it’saboutjustshowingupandprovingthatwomen canleadatthehighestlevels,”shesays.Leen’sstraightforward approachresonatesacrosstheindustry,inspiringotherwomento seetheirownpotentialinbiotechandentrepreneurship.She recognizesthatbeingoneofthefewwomentotakeabiotech companypublicismeaningful,butshe’smorefocusedon ensuringthatothersfollowherpath—andperhapsevensurpassit.
AsLeenlookstothefuture,hergoalsforPropelBioPartnersare ambitious.She’snotcontenttosimplygrowthefund;shewants tobuildaninvestmentmodelthatothersintheindustrycanlook to.Thismeansactivelyengagingwithcompaniesandsettinga newstandardforwhatinvestorscan—andshould—bringtothe tablebeyondfunding.Hereyesareonthehorizon,thinkingabout theevolutionofpatient-centrichealthcareandhowPropelBiocan playaroleinmakingitareality
Dr.Kawasisquicktopointoutthatherroleisfarfrom conventional;sheseesherselfaspartofanewbreedofinvestors whoaredeeplyinvolvedinthecompaniestheysupport.“We investmethodicallyandsupportthoughtfully,”sheexplains.For her,successisn’tjustmeasuredinreturnsbutinreal-world impact,inseeingcompaniesshebackedachievebreakthroughs thatreshapethehealthcarelandscape.
Leen’sjourneyhasnotbeenaneasyone,andthat’sexactlywhy it'ssoinspiring.Fromgroundbreakingscientificworktobreaking downgenderbarriersinbiotech,herpathhasbeenanythingbut typical.She’ssettinganexamplenotjustforfemaleleaders,but foranyonewhobelievesinthepowerofinnovationtomakea difference.
Inanindustrythat’sslowtochange,LeenKawasisacatalyst. HerworkatPropelBioPartnersisn’tjustaboutreturnsor prestige—it’saboutcreatingsomethingbiggerthanherself.She’s avisionarywho’srewritingtherulebookonwhatitmeanstolead, invest,andinnovateinbiotech.
ForDr.LeenKawas,themissionisclear:revolutionize healthcare,onebreakthroughatatime.Andasshedoes,she’s showinganentireindustrywhatitlooksliketoleadwithpurpose andpassion.
There’sareasontheworld’stopCEOs don’tbuildtheirownpayrollsoftware, CRMs,orsecuritystacksfromscratch. Theybuywhatworks—fast,proven,andscalable.
IntelligentDocumentProcessing(IDP)fallsinto thesamecategory Youdon’tbuilditunlessyour businessisinthebusinessofbuildingIDP Otherwise,you'rebleedingcashandtimeon somethingyoucouldhavedeployedweeksago.
Yeteverymonth,someambitiousteamsetsoutto buildtheirownIDP—connectingAPIs,fine-tuning models,assemblingdashboards—onlytorealize sixmonthslaterthey’veburnedamilliondollars andhaveademo,notasolution.
Ifyou’reevenaskingthe“buildvs.buy”question forIDP,here’syourrealitycheck.
What’sActuallyatStakewithIDP
Let’slevel-set.
IntelligentDocumentProcessingiswhatlets businessesextractstructureddatafromunstructured documents—invoices,contracts,emails,forms, insuranceclaims,PDFs.Anywherethere’safile, IDPiswhatletsyoupullsignalfromnoise.
Inshort:it’sthebloodstreamofAI-enabled operations.
AndtheIDPmarketisn’tsomefringeuse case—it’scompoundingat29%peryear.By2032, we’relookingatanindustryworthnearly $18billion.
Thatkindofmomentumdoesn’tcomefromniceto-haves.Itcomesfromeveryseriousenterprise realizing:“We’rewastinghoursanddollarson documentsnohumanwantstoread.”
ThemovetoIDPisobvious.
What’snotobvious—atleasttosometeams—is howtoadoptitwithoutsettingtheircompany onfire.
TheAllureofBuildingItYourself
The“build”campalwaysstartsthesameway: smartengineers,eagertostitchtogetheranIDP systemusingoff-the-shelfAPIs.
“We’ll use OpenAI for language, something opensource for layout detection, wrap it in a dashboard, and fine-tune for our use cases.”
Intheory,thatsoundsclean.
Inpractice,here’swhathappens:
· Youspend6–12monthscobblingcomponents.
· YouneedataskforceofAIengineers, annotators,opsleads,andDevSecOpsto maintainit.
· Youdiscoverthatfoundationalmodelsdon’t knowyourdocumentschema—andnowyou needexpensivepromptengineering,tuning, orcustomdatasets.
· Youdon’tactuallyautomateanything becauseyou’restuckvalidating40%of outputs.
· Youstartbuildingtoolstomaintainthetools.
Eventually,someoneasks, “Why are we building infrastructure for a commodity problem?”
Andnobodyhasagoodanswer.
RealityCheck:BuildingIDPCostsMoreThanYouThink
Let’swalkthroughtherealcostdriversofbuildingIDPin-house:
1.YouNeedSpecialistAITalent—Constantly
Thesearenotjustdatascientists.Youneedpeoplefluentin:
· Documentlayoutanalysis
· NLPpipelines
· FoundationmodelAPIsandlimits
· OCRtuninganderrorcorrection
· Post-processingworkflows
· Governanceframeworks
They’reexpensive.They’rerare.Andtheyleavefast.
2.AccuracyIsYourProblemForever
Everyusecaseyousupport—invoiceextraction,legalclause parsing,insuranceclaimtriage—requiresitsownperformance tuning.
Mostfoundationalmodelsaretrainedongeneral-purposedata. Yourdocumentsareprobablynothingliketheonesintheir trainingset.
Thismeans:
· Moreannotation
· Morepromptengineering
· Moreerrorhandling
· Moremanualreview
Youareneverdone.
3.YouInheritGovernanceHeadaches
WithgreatAIcomesgreatresponsibility:
· Howdoyouversionyourmodels?
· Whathappenswhenperformancedropsinoneregion?
· Howdoyoutrackandauditpredictions?
· Canyouprovecomplianceinregulatedindustries?
Whenyoubuildityourself,theseareyourproblems.
Youdon’tjustownthesystem.Youownitsfailure modestoo.
SoWhyDoPeopleStillTrytoBuild?
Becausethere’samyth:thatbuildingischeaperand givesyoucontrol.
Intheory,yes.Inreality,itrarelyworksoutthatway
Cheaper?Notwhenyoufactorinthetalent,the maintenance,theramp-uptime,thetechnicaldebt.
Morecontrol?You’llcontroleveryoutage,bug,and missedSLAyourself.Goodluckscalingthat.
Meanwhile,yourcompetitorsarealreadyshipping productsusingprebuiltIDPthatjustworks.
WhatSmartCompaniesDoInstead
Smartleadersdon’tbuildIDPfromscratch.
Theybuyitfromvendorswho’vealreadysolved 90%oftheproblemandspendtheirtimefocusingon the10%that’suniquetotheirbusiness.
Therearetwogoodoptions:
1.BuyIDPasastandalonepointsolution
2.Buyitembeddedwithinalargerautomation platform
Eitherway,you’restandingontheshouldersofa techstackthat’sbeenstress-testedbyglobal enterprises.
Here’swhatyougetwhenyoubuy:
1.TimetoValueinWeeks,NotQuarters
Youskipthe“build”phaseentirely.ModernIDP platformscomewith:
· Pretrainedmodels
· Out-of-the-boxintegrations
· Built-infeedbackloops
· Professionalservicesandsupport
Youcangoliveinunderamonth—notjustwitha workingmodel,butwithresultsyourCFOcansee.
2.Low-CodeTrainingThatAnyoneCanUse
NoPhDsrequired.
Best-in-classIDPletsbusinessusersannotate,correct,and improvemodelsonthefly.Thesystemlearnsfromrealworldfeedback.
Someevenuseactivelearning,wheretheAIasksforhelp onlywhenuncertain—optimizingbothaccuracyand labor
3.RiskIsOffloadedtotheVendor
Governance,monitoring,modelupdates—allthe annoyingstuffisnowsomeoneelse’sresponsibility.
Yougetuptimeguarantees.YougetSOC2compliance. Yougetredresswhenthingsgowrong.
Andwhennewmodelshitthemarket?Yougettheupgrade.
4.Built-InScale
NeedtoexpandfrominvoicestoHRfiles?Fromlegal documentstocustomerchats?
Prebuiltplatformsalreadysupportmultipleformats,use cases,andgloballanguages.
Youdon’tbuildnewmodels.Youextendexistingones.
Thisisn’tjustscale.It’scompoundingreturns
In2025,AIstrategyisnotoptional.Ifyourdocumentsare stillstuckinPDFsandemails,you’releavingmoney,time, andinsightonthetable.
Buttheworstmoveisn’ttodelayIDP.
It’stobuildyourownanddelayeverythingelse.
EverydollaryouspendreinventingtheIDPwheelisa dollarnotspentoncustomerexperience,product innovation,ormarketexpansion.
Speedwins.Precisionscales.Claritybeatscontrol.
That’stherealcalculusbehindIDP
FinalWordfromtheTrenches
Ifyourcompany’scorebusinessisnotdocumentAI,don’t pretenditis.
Buythesystem.Customizethe10%thatmatters.Focus yourenergywhereitcounts.
Andifyou’rechoosingavendor,don’tbeswayedbyflashy demosorbiglogos.
Askonequestion: Whoownstheriskwhenthisbreaks?
Iftheansweris“notus,”you’reintherightplace.
Executive Chairman In Ionis Pharmaceuticals Inc
The Antisense Architect
Dr. Stanley T. Crooke's
Legacy in Biotechnology
Dr.StanleyT.Crooke’s(Executive Chairman,IonisPharmaceuticalsInc.) storyisoneofavisionarywhotransformed thelandscapeofbiotechnology.Hisjourneyfrom humblebeginningsinIndianapolistothepinnacleof scientificinnovationisatestamenttohisrelentless pursuitofknowledgeandhisdesiretomakeatangible differenceintheworld.
Crooke’sacademicpathbeganatButlerUniversity, wherehelaidthefoundationforhisfutureinscience. HisthirstforknowledgeledhimtoBaylorCollegeof Medicine,wherehenotonlypursuedpharmacystudies butalsodelvedintothecomplexitiesofpharmacology, earningacombinedMD-PhDdegree.Abriefforay intolawschooldidnotdeterhim;instead,itreinforced hiscommitmenttomedicine.
Crooke’sresearchinpharmacologyatBaylorwasa preludetohisimpactfulworkinoncologyatBristol Laboratories.Here,hedelvedintothefightagainst cancer,contributingtothedevelopmentofnovel therapies.HistenureatSmithKline,nowknownas GlaxoSmithKline,wasmarkedbyleadershipand innovation,settingnewstandardsinpharmaceutical researchanddevelopment.
Hisworkduringthisperiodsetthestageforhisfuture endeavors,culminatinginthefoundingofIonis PharmaceuticalsInc.in1989.AsCEO,hesteeredthe companythroughtheunchartedwatersofantisense technology,facingskepticismhead-onandemergingas aleaderinRNA-targetedtherapeutics.
ThechallengesCrookefacedweremanifold,from leadingthedevelopmentofgroundbreakingtreatments toexpandingthecompany’sreachintonewtherapeutic areas.Hisleadershipwascharacterizedbya commitmenttoinnovationandscientificrigor,which becamethebedrockofIonisPharmaceuticals.
Crooke’svisionextendedbeyondthelaboratory.He soughttoimprovethelivesofpatientsandtheir families,fosteringacultureofinnovationwithinIonis.
Hismissionwasclear:toharnessantisensetechnology tocombatvariousdiseases.Thisdedicationledtothe approvalofSpinraza,alife-changingtreatmentfor spinalmuscularatrophy(SMA),andearnedhimthe prestigiousBreakthroughPrize.
Beyondhisscientificachievements,Crooke’spersonal journeyisequallyinspiring.Growingupina challengingenvironment,hedevelopedastrongwork ethicandapassionforscience,thanksinparttohis mentor,HarrisBusch.Hiscommitmenttohelping othersculminatedintheestablishmentofthen-Lorem Foundation,whichprovidesexperimentaltreatments forpatientswithraremutations.
AchievementsandAccoladestoEmbrace
Dr.Crooke’spioneeringworkhasearnedhim numeroushonors,includingthePrixGalienRoy VagelosProBonoHumanumAward,theAmerican ChemicalSociety’sE.B.HershbergAwardfor ImportantDiscoveriesinMedicinallyActive Substances,andtheLifetimeAchievementAward presentedbytheOligonucleotideTherapeutics Society.HealsoreceivedtheScripLifetime AchievementAwardandthe2019MassryPrizeforhis significantcontributionstothefieldofRNA-targeted therapeutics
In2023,CrookeretiredfromIonistofocusonhis scientificinterestsandphilanthropicwork,leaving behindalegacythatwillcontinuetoinfluencethe biotechindustryforyearstocome.
TransitioningtotheroleofExecutiveChairmanin 2023,Crookecontinuestoinfluencethetrajectoryof IonisPharmaceuticals.Hisguidanceensuresthe companyremainsatthevanguardofbiotechnology, pushingtheboundariesofwhat’spossibleindrug discoveryanddevelopment.
Hisstoryisoneofovercomingadversity,embracing challenges,andmakingalastingimpactontheworld throughscienceandcompassion.Dr.StanleyT. Crooke’snamewillforeverbesynonymouswith innovation,care,andtherelentlesspursuitofa healthierfutureforall.
SCAN & GET INSPIRED, STAY UPDATED WITH ALL THE BUSINESS WORLD BUZZ WITH GLOBAL HEALTH CARE MAGAZINE
